Mon, May 23, 2022
Sat, May 21, 2022
Fri, May 20, 2022
Thu, May 19, 2022
Wed, May 18, 2022
Tue, May 17, 2022

Christopher Raymond Maintained (BPMC) at Hold with Decreased Target to $65 on, May 19th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-65-on-may-19th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Christopher Raymond of Piper Sandler, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $84 to $65 on, May 19th, 2022.

Christopher has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 3 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $68 on, Wednesday, April 13th, 2022
  • Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Christopher


  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022

Publication Contributing Sources